KR20010080535A - 중추신경계 질환의 치료를 위한 ｎ-치환 아자비시클로알칸유도체의 용도 - Google Patents
중추신경계 질환의 치료를 위한 ｎ-치환 아자비시클로알칸유도체의 용도 Download PDFInfo
- Publication number
- KR20010080535A KR20010080535A KR1020017006445A KR20017006445A KR20010080535A KR 20010080535 A KR20010080535 A KR 20010080535A KR 1020017006445 A KR1020017006445 A KR 1020017006445A KR 20017006445 A KR20017006445 A KR 20017006445A KR 20010080535 A KR20010080535 A KR 20010080535A
- Authority
- KR
- South Korea
- Prior art keywords
- azabicyclo
- exo
- ethyl
- fluorophenyl
- heptan
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 9
- 201000010099 disease Diseases 0.000 title claims abstract description 8
- 210000003169 central nervous system Anatomy 0.000 title abstract description 3
- -1 amino, monomethylamino, dimethylamino Chemical group 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 239000011737 fluorine Substances 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 3
- 229940025084 amphetamine Drugs 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229910021386 carbon form Inorganic materials 0.000 claims description 2
- 229960003920 cocaine Drugs 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000005561 phenanthryl group Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 185
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 60
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 44
- CVIBKISSHDMEKJ-UHFFFAOYSA-N 1-ethylquinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)N(CC)C2=C1 CVIBKISSHDMEKJ-UHFFFAOYSA-N 0.000 description 40
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 28
- LETMUHYAZQNEQL-UHFFFAOYSA-N 2-ethyl-7-methyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound S1C(CC)=CN2C1=NC(C)=CC2=O LETMUHYAZQNEQL-UHFFFAOYSA-N 0.000 description 24
- YJJOJBNUDCBRTM-UHFFFAOYSA-N 5-ethyl-3,6-dimethyl-2-(methylamino)pyrimidin-4-one Chemical compound CCC1=C(C)N=C(NC)N(C)C1=O YJJOJBNUDCBRTM-UHFFFAOYSA-N 0.000 description 24
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 23
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 20
- RMHJJUOPOWPRBP-UHFFFAOYSA-N naphthalene-1-carboxamide Chemical class C1=CC=C2C(C(=O)N)=CC=CC2=C1 RMHJJUOPOWPRBP-UHFFFAOYSA-N 0.000 description 14
- VSMXLKGFTKFOSB-UHFFFAOYSA-N 1-ethyl-3h-indol-2-one Chemical compound C1=CC=C2N(CC)C(=O)CC2=C1 VSMXLKGFTKFOSB-UHFFFAOYSA-N 0.000 description 11
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 10
- JRXCUTAHLPYHAY-UHFFFAOYSA-N 1-ethylquinolin-2-one Chemical compound C1=CC=C2C=CC(=O)N(CC)C2=C1 JRXCUTAHLPYHAY-UHFFFAOYSA-N 0.000 description 9
- CIGBERQUNYDMHH-UHFFFAOYSA-N 1H-indene-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CCC2=C1 CIGBERQUNYDMHH-UHFFFAOYSA-N 0.000 description 9
- 241000156724 Antirhea Species 0.000 description 9
- 206010041349 Somnolence Diseases 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- CXUCKELNYMZTRT-UHFFFAOYSA-N 1-Ethyl-2-benzimidazolinone Chemical compound C1=CC=C2NC(=O)N(CC)C2=C1 CXUCKELNYMZTRT-UHFFFAOYSA-N 0.000 description 6
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 6
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 description 6
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 5
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 5
- 239000001273 butane Substances 0.000 description 5
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
- BWNBLGQCCSCCHF-UHFFFAOYSA-N 2-ethyl-1h-indole Chemical compound C1=CC=C2NC(CC)=CC2=C1 BWNBLGQCCSCCHF-UHFFFAOYSA-N 0.000 description 4
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 4
- DKKRVLCXVRLMMU-UHFFFAOYSA-N 3-ethyl-2-methylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC=CN2C(=O)C(CC)=C(C)N=C21 DKKRVLCXVRLMMU-UHFFFAOYSA-N 0.000 description 4
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 4
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 4
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical class C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
- HGSJSGJZOMBIAB-UHFFFAOYSA-N 2h-pyrimido[2,1-b][1,3]thiazin-6-one Chemical compound S1CC=CN2C(=O)C=CN=C21 HGSJSGJZOMBIAB-UHFFFAOYSA-N 0.000 description 3
- XFYIIXTWGSQBFN-UHFFFAOYSA-N 3-ethyl-2,7-dimethylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC(C)=CN2C(=O)C(CC)=C(C)N=C21 XFYIIXTWGSQBFN-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000003857 carboxamides Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 3
- QNPCLOIFWORBJP-UHFFFAOYSA-N 1-ethyl-6-fluoroquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC(=CC=C12)F)=O)=O QNPCLOIFWORBJP-UHFFFAOYSA-N 0.000 description 2
- HKDKELZTBPEWSU-UHFFFAOYSA-N 1-ethyl-6-methylquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC(=CC=C12)C)=O)=O HKDKELZTBPEWSU-UHFFFAOYSA-N 0.000 description 2
- LSGKMZLPZFPAIN-UHFFFAOYSA-N 1h-indole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CNC2=C1 LSGKMZLPZFPAIN-UHFFFAOYSA-N 0.000 description 2
- BYXQNAWQFGHXDQ-UHFFFAOYSA-N 2-ethyl-7-methyl-2,3-dihydro-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C(C)C1CN2C(=NC(=CC2=O)C)S1 BYXQNAWQFGHXDQ-UHFFFAOYSA-N 0.000 description 2
- LDZYRENCLPUXAX-UHFFFAOYSA-N 2-methyl-1h-benzimidazole Chemical compound C1=CC=C2NC(C)=NC2=C1 LDZYRENCLPUXAX-UHFFFAOYSA-N 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- AAIZLBJGGDQXFD-UHFFFAOYSA-N 3-ethyl-2,8-dimethylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1=C(C)C=CN2C(=O)C(CC)=C(C)N=C21 AAIZLBJGGDQXFD-UHFFFAOYSA-N 0.000 description 2
- KIYKJTIONPRZJR-UHFFFAOYSA-N 3-ethyl-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one Chemical compound CC1=CC=CN2C(=O)C(CC)=C(C)N=C21 KIYKJTIONPRZJR-UHFFFAOYSA-N 0.000 description 2
- BDTRIDKONHOQQN-UHFFFAOYSA-N 4h-pyrimidin-5-one Chemical compound O=C1CN=CN=C1 BDTRIDKONHOQQN-UHFFFAOYSA-N 0.000 description 2
- QAZLESDATKIWGZ-UHFFFAOYSA-N 5-chloro-1-ethylquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=C(C=CC=C12)Cl)=O)=O QAZLESDATKIWGZ-UHFFFAOYSA-N 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- GJYWIQVSXGWEJY-UHFFFAOYSA-N C(C)C1=CN2C(=CC(=CC2)C)S1 Chemical compound C(C)C1=CN2C(=CC(=CC2)C)S1 GJYWIQVSXGWEJY-UHFFFAOYSA-N 0.000 description 2
- GJDPKSPCTDQLKP-UHFFFAOYSA-N C(C)C1C=CN2C(S1)=NC(=CC2=O)C Chemical compound C(C)C1C=CN2C(S1)=NC(=CC2=O)C GJDPKSPCTDQLKP-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 description 2
- XRLDSWLMHUQECH-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- XNQGIOGFMATFAK-UHFFFAOYSA-N 1,3-diethylquinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(CC)C(=O)N(CC)C2=C1 XNQGIOGFMATFAK-UHFFFAOYSA-N 0.000 description 1
- QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 description 1
- WCKVTLHFRUMPJD-UHFFFAOYSA-N 1-benzyl-3-ethylquinazoline-2,4-dione Chemical compound C12=CC=CC=C2C(=O)N(CC)C(=O)N1CC1=CC=CC=C1 WCKVTLHFRUMPJD-UHFFFAOYSA-N 0.000 description 1
- LDQMACURBNQQID-UHFFFAOYSA-N 1-butylquinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)N(CCCC)C2=C1 LDQMACURBNQQID-UHFFFAOYSA-N 0.000 description 1
- YEMOSDIWPOFYPJ-UHFFFAOYSA-N 1-ethyl-3,6-dimethylpyrimidine-2,4-dione Chemical compound CCN1C(C)=CC(=O)N(C)C1=O YEMOSDIWPOFYPJ-UHFFFAOYSA-N 0.000 description 1
- WDALVHHIHIZUQY-UHFFFAOYSA-N 1-ethyl-6,7,8-trimethoxyquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC(=C(C(=C12)OC)OC)OC)=O)=O WDALVHHIHIZUQY-UHFFFAOYSA-N 0.000 description 1
- UWEZBQZUYGDKIY-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxyquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC(=C(C=C12)OC)OC)=O)=O UWEZBQZUYGDKIY-UHFFFAOYSA-N 0.000 description 1
- PIVOTOHAEKDRTL-UHFFFAOYSA-N 1-ethyl-6-(trifluoromethyl)quinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC(=CC=C12)C(F)(F)F)=O)=O PIVOTOHAEKDRTL-UHFFFAOYSA-N 0.000 description 1
- YPLDIIDRJIFICP-UHFFFAOYSA-N 1-ethyl-6-hydroxyquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC(=CC=C12)O)=O)=O YPLDIIDRJIFICP-UHFFFAOYSA-N 0.000 description 1
- HWJSQHFEPQJHMG-UHFFFAOYSA-N 1-ethyl-6-methylpyrimidine-2,4-dione Chemical compound CCN1C(C)=CC(=O)NC1=O HWJSQHFEPQJHMG-UHFFFAOYSA-N 0.000 description 1
- RQSQBVYHLGJWOC-UHFFFAOYSA-N 1-ethyl-6-nitroquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC(=CC=C12)[N+](=O)[O-])=O)=O RQSQBVYHLGJWOC-UHFFFAOYSA-N 0.000 description 1
- BBZFPVPLNWGTKT-UHFFFAOYSA-N 1-ethyl-7-fluoroquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC=C(C=C12)F)=O)=O BBZFPVPLNWGTKT-UHFFFAOYSA-N 0.000 description 1
- XDCYJSWKKNULSF-UHFFFAOYSA-N 1-ethyl-7-nitroquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC=C(C=C12)[N+](=O)[O-])=O)=O XDCYJSWKKNULSF-UHFFFAOYSA-N 0.000 description 1
- RDCWKLRJRRLPBL-UHFFFAOYSA-N 1-ethyl-8-methoxyquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC=CC(=C12)OC)=O)=O RDCWKLRJRRLPBL-UHFFFAOYSA-N 0.000 description 1
- TWFRPKKXZVEXEA-UHFFFAOYSA-N 1-ethyl-8-methylquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC=CC(=C12)C)=O)=O TWFRPKKXZVEXEA-UHFFFAOYSA-N 0.000 description 1
- ASMIAPCOQULGEO-UHFFFAOYSA-N 1-ethylthieno[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(CC)C2=C1C=CS2 ASMIAPCOQULGEO-UHFFFAOYSA-N 0.000 description 1
- PKVLOXUKWNLUNA-UHFFFAOYSA-N 1-ethylthieno[3,2-d]pyrimidine-2,4-dione Chemical compound C(C)N1C(NC(C2=C1C=CS2)=O)=O PKVLOXUKWNLUNA-UHFFFAOYSA-N 0.000 description 1
- AVSQGTAUBSVMBZ-UHFFFAOYSA-N 1-ethylthieno[3,4-d]pyrimidine-2,4-dione Chemical compound C(C)N1C(NC(C=2C1=CSC=2)=O)=O AVSQGTAUBSVMBZ-UHFFFAOYSA-N 0.000 description 1
- MGDYXRLSFHXKEL-UHFFFAOYSA-N 1-propylquinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)N(CCC)C2=C1 MGDYXRLSFHXKEL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical compound C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 description 1
- JQPYINKVAWEQDQ-UHFFFAOYSA-N 1h-pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=N1 JQPYINKVAWEQDQ-UHFFFAOYSA-N 0.000 description 1
- HMOMINHDSCYPKH-UHFFFAOYSA-N 2,5-dimethyl-1h-pyrimidin-6-one Chemical compound CC1=NC=C(C)C(=O)N1 HMOMINHDSCYPKH-UHFFFAOYSA-N 0.000 description 1
- UQFHLJKWYIJISA-UHFFFAOYSA-N 2,6-dimethyl-1h-pyrimidin-4-one Chemical compound CC1=CC(O)=NC(C)=N1 UQFHLJKWYIJISA-UHFFFAOYSA-N 0.000 description 1
- BKIGMBKKKHQCGW-UHFFFAOYSA-N 2-amino-3,5-diethyl-6-methylpyrimidin-4-one Chemical compound CCC1=C(C)N=C(N)N(CC)C1=O BKIGMBKKKHQCGW-UHFFFAOYSA-N 0.000 description 1
- ZBZFHKRVXVKBOU-UHFFFAOYSA-N 2-amino-3-ethyl-6-methylpyrimidin-4-one Chemical compound CCN1C(N)=NC(C)=CC1=O ZBZFHKRVXVKBOU-UHFFFAOYSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- QHCCOYAKYCWDOJ-UHFFFAOYSA-N 2-ethyl-1h-benzimidazole Chemical compound C1=CC=C2NC(CC)=NC2=C1 QHCCOYAKYCWDOJ-UHFFFAOYSA-N 0.000 description 1
- CJCVPBLPKUXYKO-UHFFFAOYSA-N 2-ethyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound S1C(CC)=CN2C1=NC=CC2=O CJCVPBLPKUXYKO-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- MPFMDBDLIURSOD-UHFFFAOYSA-N 2-methyl-1h-quinazoline-4-thione Chemical compound C1=CC=C2NC(C)=NC(=S)C2=C1 MPFMDBDLIURSOD-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- OGFFRHQCFMCVIQ-UHFFFAOYSA-N 3-ethyl-1,6-dimethylpyrimidine-2,4-dione Chemical compound CCN1C(=O)C=C(C)N(C)C1=O OGFFRHQCFMCVIQ-UHFFFAOYSA-N 0.000 description 1
- BPHHIFDIGVENEC-UHFFFAOYSA-N 3-ethyl-1-methylquinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(CC)C(=O)N(C)C2=C1 BPHHIFDIGVENEC-UHFFFAOYSA-N 0.000 description 1
- DFNXHNBRQIABNY-UHFFFAOYSA-N 3-ethyl-2,6,8-trimethylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1=C(C)C=C(C)N2C(=O)C(CC)=C(C)N=C21 DFNXHNBRQIABNY-UHFFFAOYSA-N 0.000 description 1
- RCSYPYSJSNRLSK-UHFFFAOYSA-N 3-ethyl-2,6-dimethylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC=C(C)N2C(=O)C(CC)=C(C)N=C21 RCSYPYSJSNRLSK-UHFFFAOYSA-N 0.000 description 1
- XPADSOPDVUAYGG-UHFFFAOYSA-N 3-ethyl-2-methoxyquinazolin-4-one Chemical compound C(C)N1C(=NC2=CC=CC=C2C1=O)OC XPADSOPDVUAYGG-UHFFFAOYSA-N 0.000 description 1
- UMQKDYHNDQNEBD-UHFFFAOYSA-N 3-ethyl-2-methylquinazolin-4-one Chemical compound C1=CC=C2C(=O)N(CC)C(C)=NC2=C1 UMQKDYHNDQNEBD-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UGCKJZOTEJEOMX-UHFFFAOYSA-N 4-[6-(4-chlorophenyl)-3-azabicyclo[3.2.0]heptan-3-yl]-1-thiophen-2-ylbutan-1-one Chemical compound C1=CC(Cl)=CC=C1C1C2CN(CCCC(=O)C=3SC=CC=3)CC2C1 UGCKJZOTEJEOMX-UHFFFAOYSA-N 0.000 description 1
- IEWMSXRYDTXBRF-UHFFFAOYSA-N 4-[6-(4-fluorophenyl)-3-azabicyclo[3.2.0]heptan-3-yl]-1-thiophen-2-ylbutan-1-one Chemical compound C1=CC(F)=CC=C1C1C2CN(CCCC(=O)C=3SC=CC=3)CC2C1 IEWMSXRYDTXBRF-UHFFFAOYSA-N 0.000 description 1
- AYESCWWMKKCHKO-UHFFFAOYSA-N 5-ethyl-1,3,6-trimethylpyrimidine-2,4-dione Chemical compound CCC1=C(C)N(C)C(=O)N(C)C1=O AYESCWWMKKCHKO-UHFFFAOYSA-N 0.000 description 1
- JCSPMARRNGTFMN-UHFFFAOYSA-N 5-ethyl-4-methoxy-N,6-dimethylpyrimidin-2-amine Chemical compound C(C)C=1C(=NC(=NC=1C)NC)OC JCSPMARRNGTFMN-UHFFFAOYSA-N 0.000 description 1
- OSRPAHRCPIGTJZ-UHFFFAOYSA-N 6-amino-1-ethylquinazoline-2,4-dione Chemical compound C1=C(N)C=C2C(=O)NC(=O)N(CC)C2=C1 OSRPAHRCPIGTJZ-UHFFFAOYSA-N 0.000 description 1
- ZXGAVIXWLAXEGE-UHFFFAOYSA-N 6-amino-3-ethyl-1-methylpyrimidine-2,4-dione Chemical compound CCN1C(=O)C=C(N)N(C)C1=O ZXGAVIXWLAXEGE-UHFFFAOYSA-N 0.000 description 1
- SDIRSOYPVNRKED-UHFFFAOYSA-N 6-ethyl-2,3,7-trimethyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C(C)C1=C(N=C2N(C1=O)C(=C(S2)C)C)C SDIRSOYPVNRKED-UHFFFAOYSA-N 0.000 description 1
- KOJIUFIJUGTHDB-UHFFFAOYSA-N 7-amino-1-ethylquinazoline-2,4-dione Chemical compound C(C)N1C(NC(C2=CC=C(C=C12)N)=O)=O KOJIUFIJUGTHDB-UHFFFAOYSA-N 0.000 description 1
- UELASANXXMJSKG-UHFFFAOYSA-N 7-chloro-1-ethylquinazoline-2,4-dione Chemical compound ClC1=CC=C2C(=O)NC(=O)N(CC)C2=C1 UELASANXXMJSKG-UHFFFAOYSA-N 0.000 description 1
- NYBDRQJPWDONJD-UHFFFAOYSA-N 7-chloro-3-ethyl-2-methylpyrimido[1,2-a]pyrimidin-4-one Chemical compound C(C)C1=C(N=C2N(C1=O)C=C(C=N2)Cl)C NYBDRQJPWDONJD-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- KIMWOULVHFLJIU-UHFFFAOYSA-N N-Methylanthranilamide Chemical compound CNC(=O)C1=CC=CC=C1N KIMWOULVHFLJIU-UHFFFAOYSA-N 0.000 description 1
- 206010034158 Pathological gambling Diseases 0.000 description 1
- QIOZLISABUUKJY-UHFFFAOYSA-N Thiobenzamide Chemical compound NC(=S)C1=CC=CC=C1 QIOZLISABUUKJY-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UMPRJGKLMUDRHL-UHFFFAOYSA-N ethyl 4-fluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C=C1 UMPRJGKLMUDRHL-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- FUZRJXVIEFEITA-UHFFFAOYSA-N n-[2-(6,6-diphenyl-3-azabicyclo[3.1.0]hexan-3-yl)ethyl]naphthalene-1-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)NCCN(C1)CC2C1C2(C=1C=CC=CC=1)C1=CC=CC=C1 FUZRJXVIEFEITA-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- FFRYUAVNPBUEIC-UHFFFAOYSA-N quinoxalin-2-ol Chemical compound C1=CC=CC2=NC(O)=CN=C21 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- IOHCGRJBQIIEOU-UHFFFAOYSA-N thiazin-6-one Chemical compound O=C1C=CC=NS1 IOHCGRJBQIIEOU-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Abstract
본 발명은 중추신경계의 중독성 질환 및 다른 질환을 치료하기 위한, 하기 화학식 Ⅰ의 N-치환 3-아자비시클로알칸 유도체의 용도에 관한 것이다.
<화학식 Ⅰ>
상기 식에서,
B, R1, R2및 n은 본 명세서에서 주어진 의미를 갖는다.
Description
N-치환 아자비시클로알칸 유도체는 신경이완제로서 이미 공지되어 있다 (국제 특허 공개 제95/13279호, 국제 특허 공개 제95/15327호, 국제 특허 공개 제96/04272호, 미국 특허 제5,475,105호, 미국 특허 제5,521,209호, 미국 특허 제5,616,705호, 미국 특허 제5,753,690호 참조). 또한 이러한 물질은 중추신경계의 중독성 질환 및 다른 질환 억제에 적합하다는 것이 밝혀져 있다.
본 발명은 중독을 억제하고, 집중 장애 (주의 결핍 장애), 아동의 활동항진 상태 (주의 결핍 활동항진 상태 장애), 학습 및 기억력 결함 (인지 능력의 손상)을 치료하는 약제 제조를 위한, 하기 화학식 Ⅰ의 N-치환 3-아자비시클로알칸 유도체 및 이들 유도체와 생리학적으로 허용되는 산과의 염의 용도를 제공한다.
상기 식에서,
B는 이중 결합을 함유할 수 있는 4-, 5- 또는 6-원 고리이며,
R1은 각각 할로겐 원자, C1-4알킬, 트리플루오로메틸, 히드록실, C1-4알콕시, 아미노, 모노메틸아미노, 디메틸아미노, 시아노 또는 니트로기에 의하여 단일치환 또는 이치환되거나, 치환되지 않은 페닐, 나프틸, 페난트릴 또는 티에닐기이고,
n은 0, 1, 2, 3 또는 4의 수이며,
R2는 1개 또는 2개의 할로겐 원자에 의하여 치환되거나, 치환되지 않은 나프틸기이거나, 또는 하기의 라디칼들 중 하나이다:
(상기 식에서,
R3은 수소 원자, 히드록실기이거나, 또는 불소, 염소 또는 브롬 원자에 의하여 치환되거나, 치환되지 않은 페닐 라디칼이고,
R4는 수소 원자이거나, 또는
R3및 R4는 함께 산소 원자이고,
R5는 각각 불소, 염소 또는 브롬 원자에 의하여, 또는 히드록실, 니트로, 아미노, C1-4알카노일아미노, C1-4알킬아미노, C1-4알킬 또는 메톡시기에 의하여 단일치환 또는 이치환되거나, 치환되지 않은 페닐, 나프틸 또는 티에닐기이며,
R6은 수소 원자 또는 메틸기이고,
R7은 각각 불소, 염소 또는 브롬 원자에 의하여, 또는 C1-4알킬, 히드록실, 메톡시, 니트로, 시아노, 트리플루오로메틸, 아미노 또는 디-C1-4알킬아미노기에 의하여 단일치환 또는 이치환되거나, 치환되지 않은 페닐, 나프틸, 벤조푸릴, 벤조티에닐, 티에닐, 인돌릴, N-메틸인돌릴 또는 인데닐기이거나, 또는 C3-7시클로알킬기이고,
R8은 수소 원자, 또는 불소 또는 염소 원자, 또는 C1-4알킬, 메톡시 또는 아미노기이며,
R9는 수소 원자 또는 메틸기이고,
R10은 수소 원자 또는 메틸기이거나, 또는
R9와 R10은 고리 탄소 원자와 함께 스피로시클로프로판 고리를 형성하고,
R11은 수소 원자, 히드록실, C1-C4알킬 또는 C1-C4알콕시기이거나, 인접한 탄소 원자와 함께 C=O- 또는 C=S기를 형성하고,
X 및 Y는 탄소 원자, CH, CH2, NH 또는 C1-C4알킬-N기, 또는 질소 원자이고,
Z는 직접 결합, CO기, CS기이거나, 또는 수소 원자가 히드록실, 아미노 또는 C1-C4알콕시기에 의하여 또는 할로겐 원자에 의하여 치환될 수 있는 CH 또는 CH2기이고,
A는 수소 원자, 히드록실, 아미노, 메르캅토, C1-C4알킬아미노, 디-C1-C4알킬아미노, C1-C4알킬티오 또는 C1-C4알콕시기이거나, 인접한 탄소 원자와 함께 C=O기를 형성하거나, 또는
A는 이중 결합을 비연속적으로 1개 또는 2개 함유할 수 있고 CH 또는 CH2기 중 하나가 질소 또는 황 원자에 의하여 또는 NH 또는 N-CH3기에 의하여 대체될 수 있는, Y에 결합된 C3-C4알킬렌기이고, 이와 같은 A 함유 고리는 불소 또는 염소 원자에 의하여, 또는 메틸, 메톡시, 니트로 또는 아미노기에 의하여 단일 치환되고, 상기 고리가 벤젠 고리인 경우, 이 고리는 불소 또는 염소 원자 또는 메틸, 트리플루오로메틸, 니트로, 히드록실, 메톡시, 아미노, 모노메틸 또는 디메틸아미노기에 의하여 단일치환, 이치환, 또는 삼치환될 수 있으며,
X-, Y- 및 Z-함유 고리는 1번 질소 원자에서 C1-C4알킬, 알릴 또는 벤질기를 가질 수 있으며, 이중 결합을 비연속적으로 1개 내지 3개 함유할 수 있다).
본 발명에 따른 용도는 물질의 남용에 의한 중독성 질환, 또는 예를 들어 도박 중독과 같은 다른 중독성 질환을 불문하고 모든 중독성 질환과 관련이 있다. 습관성 물질로는, 예를 들어 모르핀 또는 헤로인과 같은 오피오이드; 니코틴; 알콜; 및 예를 들어 벤조디아제핀과 같은 벤조디아제핀 수용체 복합체와 상호작용하는 물질, 진정제 또는 신경안정제가 있을 수 있다.
본 발명에 따른 습관성 물질로 가능한 것은 특히, 코카인 또는 암페타민 및암페타민계 물질이다.
화학식 Ⅰ의 화합물은 이들의 라세미체 및 광학 이성질체 둘다의 형태로 사용될 수 있다.
신규한 적용을 위하여, 상기 화합물은 통상적인 방법에 의하여 경구적 또는 비경구적, 정맥내 또는 근육내로 투여될 수 있다.
투여량은 환자의 연령, 상태 및 체중, 그리고 투여형에 좌우된다. 일반적으로 활성 화합물의 1일 투여량은 경구 투여인 경우에는 체중 1kg 당 약 1 내지 100 mg이며, 비경구 투여인 경우에는 체중 1kg 당 약 0.1 내지 10 mg이다.
상기 화합물은 통상적인 제약 투여형, 예를 들어, 정제, 필름 제피정 (film-coated tablets), 캡슐, 분말, 과립, 당의정, 좌제, 용액, 연고, 크림 또는 스프레이 같은 고상물 또는 액상물 형태로서 사용될 수 있다. 이들은 통상적인 방법으로 제조된다. 이러한 목적으로, 상기 활성 화합물은 정제 결합제, 충전제, 보존제, 정제 붕해제, 유동 조절제, 가소제, 습윤제, 분산제, 유화제, 용매, 방출-지연제, 산화방지제 및(또는) 추진제와 같은 통상적인 제약 보조제와 함께 가공될 수 있다 (서커 (H. Sucker) 등의 문헌 [Pharmazeutische Technologie (Pharmaceutical Technology), Thieme-Verlag, Stuttgart, 1978] 참조). 이렇게 하여 얻어진 투여 형태는 일반적으로 활성 화합물을 1 내지 99 중량%의 양으로 포함한다.
하기의 물질들은 화학식 Ⅰ의 화합물의 예로서 언급될 수 있다.
1. 1-(4-플루오로페닐)-4-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
2. 1-페닐-4-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]-부탄-1-온
3. 1-(4-플루오로페닐)-4-[엑소-6,7-디페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
4. 1-(4-플루오로페닐)-4-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄
5. 1-페닐-2-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에탄-1-온
6. 1-(4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄
7. 1-(4-플루오로페닐)-4-[엑소-6-m-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
8. 1-(4-플루오로페닐)-4-[엑소-6-o-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
9. 1-(4-플루오로페닐)-4-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
10. 1-(4-플루오로페닐)-4-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
11. 1-(4-플루오로페닐)-4-[엑소-6-p-메톡시페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
12. 1-(4-플루오로페닐)-4-[엑소-6-m,p-디클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
13. 1-(4-플루오로페닐)-4-[엑소-6-m,p-디메톡시페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
14. 1-(4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
15. 1-페닐-4-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
16. 1-(4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄
17. 1-(4-플루오로페닐)-4-[엑소-6-p-니트로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
18. 1-(4-플루오로페닐)-4-[엑소-6-m-니트로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
19. 1-(4-플루오로페닐)-4-[엑소-6-p-트리플루오로메틸페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
20. 1-(4-플루오로페닐)-4-[엑소-6-p-시아노페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
21. 1-(4-플루오로페닐)-4-[엑소-6-티엔-3-일-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
22. 1-(4-플루오로페닐)-4-[엑소-6-피리드-3-일-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
23. 1-(4-플루오로페닐)-3-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로판-1-온
24. 1-(비스-4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-3-아자비시클로
[3.2.0]헵탄-3-일]부탄
25. 1-(비스-4-플루오로페닐)-4-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄
26. 1-(4-플루오로페닐)-4-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-올
27. 1-(4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-올
28. 1-(4-플루오로페닐)-4-[엑소-6,7-디페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-올
29. 1-페닐-4-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-올
30. 1-페닐-4-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-올
31. 1-(4-플루오로페닐)-4-[엑소-6-o-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-올
32. 1-(4-플루오로페닐)-4-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-올
33. 1-(4-플루오로페닐)-4-[엑소-6-p-트리플루오로메틸페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-올
34. 1-(4-플루오로페닐)-4-[엑소-6-p-아미노페닐-3-아자비시클로[3.2.0]헵탄-3-일]부탄-1-온
35. N-(3-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필)-4-플루오로벤즈아미드
36. N-(3-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필)벤즈아미드
37. N-(2-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-4-플루오로벤즈아미드
38. N-(2-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤즈아미드
39. N-(2-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-N-메틸-4-플루오로벤즈아미드
40. N-(2-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-N-메틸벤즈아미드
41. N-(2-[엑소-6-페닐-3-아자비시클로[3-2.0]헵탄-3-일]에틸)-N-메틸-4-이소프로필벤즈아미드
42. N-(3-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필)-4-클로로벤즈아미드
43. N-(2-[엑소-6-p-트리플루오로메틸페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸)-4-클로로벤즈아미드
44. N-(3-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필)-3-메톡시벤즈아미드
45. N-(3-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필)-3-니트로벤즈아미드
46. N-(3-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필)-4-플루오로벤즈아미드
47. N-(3-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필)벤즈아미드
48. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-4-플루오로벤즈아미드
49. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤즈아미드
50. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-N-메틸-4-플루오로벤즈아미드
51. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-N-메틸벤즈아미드
52. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-N-메틸-4-이소프로필벤즈아미드
53. N-(3-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필)-4-클로로벤즈아미드
54. N-(3-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필)-3-메톡시벤즈아미드
55. N-(3-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필)-3-니트로벤즈아미드
56. N-(2-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-4-클로로벤즈아미드
57. N-(2-[엑소-6-o-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸)-4-클로로벤즈아미드
58. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸)-2-히드록시벤즈아미드
59. N-(2-[엑소-6-m-히드록시페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-4-클로로벤즈아미드
60. 엑소-3-n-부틸-6-페닐-3-아자비시클로[3.2.0]헵탄
61. 엑소-3-메틸-6-페닐-3-아자비시클로[3.2.0]헵탄
62. 엑소-3-메틸-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄
63. 엑소-3-n-프로필-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄
64. 엑소-3-메틸-6,7-디페닐-3-아자비시클로[3.2.0]헵탄
65. 엑소-3-n-프로필-6-m-히드록시페닐-3-아자비시클로[3.2.0]헵탄
66. 엑소-3-알릴-6-m-메톡시페닐-3-아자비시클로[3.2.0]헵탄
67. 엑소-3-(3,4-디메톡시)펜에틸-6-페닐-3-아자비시클로[3.2.0]헵탄
68. 엑소-3-(3,4-디메톡시)펜에틸-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄
69. 엑소-3-(3,4-디히드록시)펜에틸-3-아자비시클로[3.2.0]헵탄
70. 엑소-3-펜에틸-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄
71. 6-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
72. (+)-6-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
73. (-)-6-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
74. 6-β-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
75. 6-β-[엑소-6,7-디페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
76. 6-β-[엑소-6,7-비스-(p-플루오로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
77. 6-β-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
78. 6-β-[엑소-6-m-메톡시페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
79. 6-β-[엑소-6-m-히드록시페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
80. 6-β-(2-[엑소-6-p-아미노페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
81. 6-β-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
82. 6-β-[엑소-6-p-메톡시페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
83. 6-β-[엑소-6-p-니트로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
84. 6-β-[엑소-6-m-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
85. 6-β-[엑소-6-p-히드록시페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
86. 6-β-[엑소-6-p-트리플루오로메틸페닐-3-아자비시클로[3.2.0]-헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
87. 6-β-[엑소-6-(p-t-부틸페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
88. 6-β-[엔도-6-(p-t-부틸페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
89. 6-β-[엑소-6-(3,4-디클로로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
90. 6-β-[엑소-6-(3,4-디메톡시페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
91. 6-β-[엑소-6-p-시아노페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
92. 6-β-[엑소-6-(3,4-디히드록시페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
93. 6-β-[엑소-6-(o-플루오로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
94. 6-β-[엑소-6-티엔-3-일-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
95. 6-β-[엑소-6-(5-클로로티엔-2-일)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
96. 6-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-7-메틸-2,3-디히드로-5H-티아졸로[3,2-a]피리미딘-5-온
97. 6-β-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-7-메틸-2,3-디히드로-5H-티아졸로[3,2-a]피리미딘-5-온
98. 6-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,3,7-트리메틸-5H-티아졸로[3,2-a]피리미딘-5-온
99. 6-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-5H-티아졸로[3,2-a]피리미딘-5-온
100. 6-β-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-5H-티아졸로
[3,2-a]피리미딘-5-온
101. 7-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-8-메틸-2H,6H-피리미도[2,1-b][1,3]티아진-6-온
102. 7-β-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-8-메틸-2H,6H-피리미도[2,1-b][1,3]티아진-6-온
103. 7-β-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.O]헵탄-3-일]-에틸-8-메틸-2H,6H-피리미도[2,1-b][1,3]티아진-6-온
104. 7-β-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.O]헵탄-3-일]-에틸-8-메틸-2H,6H-피리미도[2,1-b][1,3]티아진-6-온
105. 7-β-[엑소-6-p-메톡시페닐-3-아자비시클로[3.2.O]헵탄-3-일]-에틸-8-메틸-2H,6H-피리미도[2,1-b][1.3]티아진-6-온
106. 7-β-[엑소-6-m-히드록시페닐-3-아자비시클로[3.2.O]헵탄-3-일]-에틸-8-메틸-2H,6H-피리미도[2,1-b][1,3]티아진-6-온
107. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
108. (+)-3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
109. (-)-3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
110. 3-β-[엑소-6-페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
111. 3-β-[엑소-6-m-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
112. 3-β-[엑소-6-p-시아노페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
113. 3-β-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
114. 3-β-[엑소-6-p-히드록시페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
115. 3-β-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
116. 3-β-[엑소-6-m-메톡시페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
117. 3-β-[엑소-6-p-니트로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
118. 3-β-[엔도-6-p-니트로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
119. 3-β-[엑소-6-m-히드록시페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
120. 3-β-[엑소-6-p-아미노페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
121. 3-β-[엑소-6-p-요오도페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
122. 3-β-[엑소-6-p-트리플루오로메틸페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
123. 3-β-[엑소-6-(3,4-디클로로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
124. 3-β-[엑소-6-(3,4-디히드록시페닐)-3-아자비시클로[3.2.O]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
125. 3-β-[엑소-6-(3,5-디클로로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
126. 3-β-[엑소-6-o-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
127. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-8-메틸-2,4-(1H,3H)퀴나졸린디온
128. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-7-클로로-2,4-(1H,3H)퀴나졸린디온
129. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-7-플루오로-2,4-(1H,3H)퀴나졸린디온
130. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-5-클로로-2,4-(1H,3H)퀴나졸린디온
131. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-6-플루오로-2,4-(1H,3H)퀴나졸린디온
132. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-6-메틸-2,4-(1H,3H)퀴나졸린디온
133. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-8-메톡시-2,4-(1H,3H)퀴나졸린디온
134. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-6-트리플루오로메틸-2,4-(1H,3H)퀴나졸린디온
135. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-니트로-2,4-(1H,3H)퀴나졸린디온
136. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-6-니트로-2,4-(1H,3H)퀴나졸린디온
137. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-아미노-2,4-(1H,3H)퀴나졸린디온
138. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-6-아미노-2,4-(1H,3H)퀴나졸린디온
139. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-6-히드록시-2,4-(1H,3H)퀴나졸린디온
140. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-5-클로로-2,4-(1H,3H)퀴나졸린디온
141. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-6,7-디메톡시-2,4-(1H,3H)퀴나졸린디온
142. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-6,8-디클로로-2,4-(1H,3H)퀴나졸린디온
143. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-6,7,8-트리메톡시-2,4-(1H,3H)퀴나졸린디온
144. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1-메틸-2,4-(1H,3H)퀴나졸린디온
145. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1-에틸-2,4-(1H,3H)퀴나졸린디온
146. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1-알릴-2,4-(1H,3H)퀴나졸린디온
147. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1-벤질-2,4-(1H,3H)퀴나졸린디온
148. 3-γ-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]프로필-2,4-(1H,3H)퀴나졸린디온
149. 3-δ-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]부틸-2,4-(1H,3H)퀴나졸린디온
150. 3-β-[엑소-6-(2-티에닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
151. 3-β-[엑소-6-(5-클로로-2-티에닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
152. 3-β-[엑소-6-(3-티에닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
153. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1H-티에노[3,2-d]피리미딘-2,4-디온
154. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1H-티에노[2,3-d]피리미딘-2,4-디온
155. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1H-티에노[3,4-d]피리미딘-2,4-디온
156. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-에틸-1-메틸-1H,3H-피리도[2,3-d]피리미딘-2,4-디온
157. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸-3H-퀴나졸린-4-온
158. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메톡시-3H-퀴나졸린-4-온
159. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-에틸-2-메틸-4H-피리도[1,2-a]피리미딘-4-온 디히드로클로라이드
160. 3-β-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸-4H-피리도[1,2-a]피리미딘-4-온
161. 3-β-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸-4H-피리도[1,2-a]피리미딘-4-온
162. 3-β-[엑소-6-m-메톡시페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸-4H-피리도[1,2-a]피리미딘-4-온
163. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-2,6-디메틸-4H-피리도[1,2-a]피리미딘-4-온
164. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,7-디메틸-4H-피리도[1,2-a]피리미딘-4-온
165. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,8-디메틸-4H-피리도[1,2-a]피리미딘-4-온
166. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,9-디메틸-4H-피리도[1,2-a]피리미딘-4-온
167. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,6,8-트리메틸-4H-피리도[1,2-a]피리미딘-4-온
168. 3-β-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,7-디메틸-4H-피리도[1,2-a]피리미딘-4-온
169. 3-β-[엑소-6-o-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,7-디메틸-4H-피리도[1,2-a]피리미딘-4-온
170. 3-β-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,8-디메틸-4H-피리도[1,2-a]피리미딘-4-온
171. 3-β-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,9-디메틸-4H-피리도[1,2-a]피리미딘-4-온
172. 3-β-[엑소-6-(5-클로로티엔-2-일)-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸-4H-피리도[1,2-a]피리미딘-4-온
173. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-에틸-6,7,8,9-테트라히드로-2-메틸-4H-피리도[l,2-a]피리미딘-4-온
174. 3-β-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-에틸-6,7,8,9-테트라히드로-2-메틸-4H-피리도[1,2-a]피리미딘-4-온
175. 3-β-[엑소-6-p-메톡시페닐-3-아자비시클로[3.2.0]헵탄-3-일]-에틸-6,7,8,9-테트라히드로-2-메틸-4H-피리도[1,2-a]피리미딘-4-온
176. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸-4H-피리미도[1,2-a]피리미딘-4-온
177. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸-2-메틸-7-클로로-4H-피리미도[1,2-a]피리미딘-4-온
178. 6-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-7-메틸-1H,5H-이미다조[l,2-a]피리미딘-5-온
179. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸-7,8-디히드로-4H,6H-피롤로[1,2-a]피리미딘-4-온
180. 2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸벤즈이미다졸
181. 1-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸벤즈이미다졸
182. 1-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2,3-디히드로벤즈이미다졸-2-온
183. 2-[엑소-6-m-메톡시페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸벤즈이미다졸
184. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸인돌, m.p. 193-195℃ (히드로클로라이드)
185. 3-β-(2-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸인돌
186. 3-β-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸인돌,
m.p. 104-105℃ (히드로클로라이드)
187. 3-β-[엑소-6-m-메톡시페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸인돌
188. 2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸-3,4-디히드로퀴나졸린-4-온
189. 2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸-3,4-디히드로퀴나졸린-4-티온
190. 2-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸-3,4-디히드로퀴나졸린-4-온
191. 2-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸-3,4-디히드로퀴나졸린-4-온
192. 2-[엑소-6-o-메톡시페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸-3,4-디히드로퀴나졸린-4-온
193. 2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸-4-히드록시-6-메틸피리미딘
194. 6-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸-2-메틸-4-히드록시피리미딘
195. 6-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸우라실
196. 6-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]메틸우라실
197. 6-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-1,2,3,4-테트라히드로-1,3-디메틸-2,4-디옥소피리미딘
198. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1,2,3,4-테트라히드로-6-메틸-2,4-디옥소피리미딘
199. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1,2,3,4-테트라히드로-1,6-디메틸-2,4-디옥소피리미딘
200. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1,2,3,4-테트라히드로-3,6-디메틸-2,4-디옥소피리미딘
201. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1,2,3,4-테트라히드로-3,6-디메틸-2,4-디티오피리미딘
202. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1,2,3,4-테트라히드로-1,3,6-트리메틸-2,4-디옥소피리미딘
203. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-1,2,3,4-테트라히드로-6-아미노-1-메틸-2,4-디옥소피리미딘
204. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-아미노-6-메틸-4(3H)피리미디논
205. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-아미노-3,6-디메틸-4(3H)피리미디논
206. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
207. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸아미노-3-에틸-6-메틸-4(3H)피리미디논
208. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-아미노-3-에틸-6-메틸-4(3H)피리미디논
209. 5-β-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
210. 5-β-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
211. 5-β-[엑소-6-o-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
212. 5-β-[엑소-6-p-트리플루오로메틸페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
213. 5-β-[엑소-6-p-시아노페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
214. 5-β-[엑소-6-m-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
215. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-2-메틸아미노-4-메톡시-6-메틸피리미딘
216. 3-β-[엑소-6-페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
217. 3-β-[엔도-6-페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
218. 3-β-[엑소-6-p-플루오로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
219. 3-β-[엑소-6-p-트리플루오로메틸페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸-6-플루오로-2,4-(1H,3H)퀴나졸린디온
220. 3-β-[엑소-6-m-클로로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
221. 3-β-[엑소-6-p-메톡시페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸-6-메틸-2,4-(1H,3H)퀴나졸린디온
222. 5-β-[엑소-6-페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]-옥탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
223. 5-β-[엑소-6-p-플루오로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
224. 1-β-[엑소-6-p-플루오로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸-2(3H)벤즈이미다졸론
225. 5-β-[엑소-6-p-니트로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
226. 5-β-[엑소-6-페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]-옥탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
227. 5-β-[엔도-6-페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]-옥탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
228. 3-β-[엑소-6-p-플루오로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸-2-메틸-4H-피리도[l.2-a]피리미딘-4-온
229. 1-β-[엑소-6-p-플루오로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸인돌린-2-온
230. 6-β-[엑소-6-p-플루오로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸-7-메틸-5H-티아졸로[3.2-a]피리미딘-5-온
231. 1-β-[엑소-6-p-플루오로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸-2(1H)퀴놀론
232. 3-β-[7-페닐-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
233. 3-β-[7-p-플루오로페닐-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
234. 5-β-[7-p-플루오로페닐-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
235. 3-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.1.0]헥산-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
236. 3-β-[엑소-6-페닐-3-아자비시클로[3.1.0]헥산-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
237. 3-β-[6,6-디페닐-3-아자비시클로[3.1.0]헥산-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
238. 5-β-[엑소-6-p-플루오로페닐-3-아자비시클로[3.1.0]헥산-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
239. 6-β-[엑소-6-m-클로로페닐-3-아자비시클로[3.1.0]헥산-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
240. 3-β-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥트-6-엔-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
241. 5-β-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥트-6-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
242. 6-β-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥트-6-엔-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
243. 1-β-[6-페닐-1,5-시스-3-아자비시클로[3.3.0]옥트-6-엔-3-일]에틸-2(3H)벤즈이미다졸론
244. 1-β-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥트-6-엔-3-일]에틸인돌린-2-온
245. 1-β-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥트-6-엔-3-일]에틸-2(1H)퀴놀론
246. 3-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
247. 5-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
248. 6-β-[엑소-6-페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
249. 1-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸인돌린-2-온
250. 1-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.O]옥탄-3-일]에틸-2(1H)퀴놀론
251. 3-β-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
252. 5-β-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
253. 6-β-[엔도페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸-7-메틸-5H-티아졸로[3.2-a]피리미딘-5-온
254. 1-β-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸인돌린-2-온
255. 1-β-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸-2(1H)퀴놀론
256. 3-β-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
257. 5-β-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
258. 6-β-[엑소-7-페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸-7-메틸-5H-티아졸로[3.2-a]피리미딘-5-온
259. 1-β-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸인돌린-2-온
260. 1-β-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.O]옥탄-3-일]에틸-2(1H)퀴놀론
261. 3-β-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
262. 5-β-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
263. 3-β-[엔도-6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
264. 5-β-[엔도-6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
265. 3-β-[엔도-6-p-트리플루오로메틸페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
266. 5-β-[엔도-6-p-트리플루오로메틸페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
267. 3-β-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
268. 5-β-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
269. 1-β-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸-2(3H)벤즈이미다졸론
270. 1-β-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.O]논-7-엔-3-일]에틸인돌린-2-온
271. 3-β-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
272. 5-β-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
273. 3-β-[6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
274. 5-β-[6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
275. 3-β-[6-p-트리플루오로메틸페닐-1,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
276. 5-β-[6-p-트리플루오로메틸페닐-1,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
277. 1-β-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸-2(3H)벤즈이미다졸론
278. 1-β-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸인돌린-2-온
279. 1-β-[6-p-플루오로페닐-l,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸-2(1H)퀴놀론
280. 3-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸-2,4-(1H,3H)퀴나졸리돈
281. 5-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
282. 3-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸-2-메틸-4H-피리도[1.2-a]피리미딘-4-온
283. 1-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸-2(1H)퀴놀론
284. 1-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸-2(3H)벤즈이미다졸론
285. 1-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸인돌린-2-온
286. 3-β-[엑소-6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
287. 5-β-[엑소-6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]-에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
288. 3-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
289. 5-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
290. 3-β-[엑소-6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
291. 5-β-[엑소-6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
292. 6-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-7-메틸-5H-티아졸로[3.2-a]피리미딘-5-온
293. 1-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2(3H)벤즈이미다졸론
294. 1-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸인돌린-2-온
295. 1-β-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2(1H)퀴놀론
296. 3-β-[엑소-7-페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
297. 5-β-[엑소-7-페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
298. 3-β-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
299. 5-β-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
300. 3-β-[7-p-플루오로페닐-3-아자비시클로[4.3.0]논-1-엔-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
301. 5-β-[7-페닐-3-아자비시클로[4.3.0]논-1-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
302. 5-β-[7-p-플루오로페닐-3-아자비시클로[4.3.0]논-1-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
303. 3-β-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
304. 5-β-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.O]논-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
305. 1-β-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸-2(3H)벤즈이미다졸론
306. 1-β-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸인돌린-2-온
307. 1-β-[엑소-7-p-플루오로페닐-l,5-시스-3-아자비시클로[4.3.O]논-3-일]에틸-2(1H)퀴놀론
308. 3-β-[6-p-플루오로페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥트-6-엔-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
309. 5-β-[6-p-플루오로페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥트-6-엔-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
310. 3-β-[엑소/엔도-6-p-플루오로페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]-옥탄-3-일]에틸-2,4-(1H,3H)퀴나졸린디온
311. 5-β-[엑소/엔도-6-p-플루오로페닐-l,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸-2-메틸아미노-3,6-디메틸-4(3H)피리미디논
312. 1-β-[6-p-플루오로페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥트-6-엔-3-일]에틸인돌린-2-온
313. 6-β-[6-페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥트-6-엔-3-일]에틸-7-메틸-5H-티아졸로[3,2-a]피리미딘-5-온
314. N-(2-[엑소-6-페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸)-4-플루오로벤즈아미드
315. N-(2-[엔도-6-페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸)-4-플루오로벤즈아미드
316. N-(2-[엑소-6-p-플루오로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸)-4-플루오로벤즈아미드
317. N-(2-[엑소-6-p-트리플루오로메틸페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸)벤즈아미드
318. N-(2-[엑소-6-m-클로로페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸)벤즈아미드
319. N-(2-[엑소-6-p-메톡시페닐-7-메틸-1,5-시스-3,7-디아자비시클로
[3.3.0]옥탄-3-일]에틸)-4-클로로벤즈아미드
320. N-(2-[엑소-6-페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸)나프탈렌-1-카르복스아미드
321. 1-(4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]부탄-1-온
322. 1-(4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-7-메틸-1,5-시스-3,7-디아자비시클로[3.3.0]옥탄-3-일]부탄-1-올
323. N-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)벤즈아미드
324. 1-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)나프탈렌
325. 1-(4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]부탄-1-온
326. 1-(4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]부탄-1-올
327. N-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)-2-(N-메틸)아미노벤즈아미드
328. N-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)-5-클로로티엔-2-일카르복스아미드
329. N-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)인덴-3-카르복스아미드
330. N-(2-[엑소-6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)-4-플루오로벤즈아미드
331. N-(2-[엑소-6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)나프탈렌-1-카르복스아미드
332. 1-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸)나프탈렌
333. 1-(4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]부탄-1-온
334. N-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸)벤즈아미드
335. N-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸)인덴-3-카르복스아미드
336. N-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸)나프탈렌-1-카르복스아미드
337. N-(2-[엑소-6-페닐-1,5-시스-3-아자비시클로[4.3.O]논-7-엔-3-일]에틸)-4-플루오로벤즈아미드
338. N-(2-[엑소-6-페닐-1,5-시스-3-아자비시클로[4.3.O]논-7-엔-3-일]에틸)-3-클로로-1-벤조티엔-2-일카르복스아미드
339. 1-(2-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸)나프탈렌
340. 1-(4-플루오로페닐)-4-[6-p-플루오로페닐-1,5-시스-3-아자비시클로
[4.3.0]논-6-엔-3-일]부탄-1-온
341. 1-(4-플루오로페닐)-4-[6-p-플루오로페닐-1,5-시스-3-아자비시클로
[4.3.0]논-6-엔-3-일]부탄-1-올
342. N-(2-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.O]논-6-엔-3-일]에틸)-2-(N-메틸)아미노벤즈아미드
343. N-(2-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.O]논-6-엔-3-일]에틸)-5-클로로티엔-2-일카르복스아미드
344. N-(2-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.O]논-6-엔-3-일]에틸)벤즈아미드
345. N-(2-[6-페닐-1,5-시스-3-아자비시클로[4.3.O]논-6-엔-3-일]에틸)-3-클로로-1-벤조티엔-2-일카르복스아미드
346. N-(2-[6-p-트리플루오로메틸페닐-1,5-시스-3-아자비시클로[4.3.0]논-6-엔-3-일]에틸)나프탈렌-1-카르복스아미드
347. N-(2-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.O]논-6-엔-3-일]에틸)인덴-3-카르본이미드
348. N-(2-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.O]논-6-엔-3-일]에틸)나프탈렌-1-카르복스아미드
349. 1-(2-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)나프탈렌
350. 1-(4-플루오로페닐)-4-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]부탄-1-온
351. 1-(4-플루오로페닐)-4-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]부탄-1-올
352. N-(2-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]-2-(N-메틸)아미노벤즈아미드
353. N-(2-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)벤즈아미드
354. N-(2-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.O]논-3-일]에틸)-5-클로로티엔-2-일카르복스아미드
355. N-(2-[엔도-6-페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)-4-플루오로벤즈아미드
356. N-(2-[엔도-6-p-트리플루오로메틸페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)인덴-3-카르복스아미드
357. 2-(2-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸)나프탈렌
358. N-(2-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸)벤즈아미드
359. N-(2-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸)-2-(N-메틸)아미노벤즈아미드
360. N-(2-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-7-엔-3-일]에틸)나프탈렌-1-카르복스아미드
361. 1-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]에틸)나프탈렌
362. 1-(4-플루오로페닐)-4-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]부탄-1-온
363. N-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]에틸)벤즈아미드
364. N-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]에틸)-5-클로로티엔-2-일카르복스아미드
365. N-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]에틸)-3-클로로-1-벤조티엔-2-일카르복스아미드
366. N-(2-[엑소-7-페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]에틸)인덴-3-카르복스아미드
367. N-(2-[엑소-7-페닐-1,5-시스-3-아자비시클로[4.3.0]논-8-엔-3-일]에틸)나프탈렌-1-카르복스아미드
368. 1-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)나프탈렌
369. 1-(4-플루오로페닐)-4-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]부탄-1-온
370. 1-(4-플루오로페닐)-4-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]부탄-1-올
371. N-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)-2-(N-메틸)아미노벤즈아미드
372. N-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)벤즈아미드
373. N-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)-5-클로로티엔-2-일카르복스아미드
374. N-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)나프탈렌-1-카르복스아미드
375. N-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[4.3.0]논-3-일]에틸)인덴-3-카르복스아미드
376. 1-(2-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥트-6-엔-3-일]에틸)나프탈렌
377. 1-(4-플루오로페닐)-4-[6-p-플루오로페닐-1,5-시스-3-아자비시클로
[3.3.0]옥트-6-엔-3-일]부탄-1-온
378. N-(2-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥트-6-엔-3-일]에틸)벤즈아미드
379. N-(2-[6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥트-6-엔-3-일]에틸)나프탈렌-1-카르복스아미드
380. 1-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)나프탈렌
381. 1-(4-플루오로페닐)-4-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]부탄-1-올
382. N-(2-[엑소-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)벤즈아미드
383. N-(2-[엑소-6-페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)나프탈렌-1-카르복스아미드
384. N-(2-[엑소-6-페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)인덴-3-카르복스아미드
385. 1-(2-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)나프탈렌
386. 1-(4-플루오로페닐)-4-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]부탄-1-온
387. N-(2-[엔도-6-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)벤즈아미드
388. N-(2-[엔도-6-페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)나프탈렌-1-카르복스아미드
389. 1-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)나프탈렌
390. 1-(4-플루오로페닐)-4-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]부탄-1-온
391. N-(2-[엑소-7-p-플루오로페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)벤즈아미드
392. N-(2-[엑소-7-페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)나프탈렌-1-카르복스아미드
393. N-(2-[엑소-7-페닐-1,5-시스-3-아자비시클로[3.3.0]옥탄-3-일]에틸)인덴-3-카르복스아미드
394. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.1.0]헥산-3-일]에틸)-4-플루오로벤즈아미드
395. N-(2-[엑소-6-페닐-3-아자비시클로[3.1.0]헥산-3-일]에틸)-5-클로로티엔-2-일카르복스아미드
396. N-(2-[6,6-디페닐-3-아자비시클로[3.1.0]헥산-3-일]에틸)나프트-1-일카르복스아미드
397. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.1.O]헥산-3-일]에틸)-3-클로로-1-벤조티엔-2-일카르복스아미드
398. N-(2-[엑소-6-m-클로로페닐-3-아자비시클로[3.1.0]헥산-3-일]에틸)-4-클로로벤즈아미드
399. 1-(2-[6-p-플루오로페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥트-6-엔-3-일]에틸)나프탈렌
400. N-(2-[6-p-플루오로페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.O]옥트-6-엔-3-일]에틸)벤즈아미드
401. N-(2-[6-p-플루오로페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥트-6-엔-3-일]에틸)나프탈렌-1-카르복스아미드
402. N-(2-[6-p-플루오로페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥트-6-엔-3-일]에틸)인덴-3-카르복스아미드
403. 1-(2-[엑소/엔도-6-p-플루오로페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸)나프탈렌
404. N-(2-[엑소/엔도-6-p-플루오로페닐-1,5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥탄-3-일]에틸)벤즈아미드
405. 1-(2-[6-페닐-1-5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥트-6-엔-3-일]에틸)나프탈렌
406. N-(2-[6-페닐-1-5-시스-8-옥사-3,7-디아자비시클로[3.3.0]옥트-6-엔-3-일]에틸)벤즈아미드
407. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤조술폰아미드
408. N-(2-[엑소-6-페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤조술폰아미드
409. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-N-메틸벤조술폰아미드
410. N-(2-[엑소-6-(5-클로로티엔-2-일)-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-4-플루오로벤조술폰아미드
411. 3-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-1-페녹시프로판
412. 2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-1-p-플루오로페녹시에탄
413. 3-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-1-(1-나프틸옥시)프로판
414. 3-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-1-p-t-부틸페녹시프로판
415. 3-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]-1-p-플루오로페녹시프로판
416. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)티오벤즈아미드
417. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-4-플루오로티오벤즈아미드
418. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-4-클로로티오벤즈아미드
419. O-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤조에이트
420. 0-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸-4-플루오로벤조에이트
421. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-1H-벤조[cd]인돌-2-온
422. N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸)-1H-벤조[cd]인돌-2-온
423. N-(2-[엑소-6-m-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸)-1H-벤조[cd]인돌-2-온
424. N-(2-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸)-1H-벤조[cd]인돌-2-온
425. 3,3-디메틸-1-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)인돌린-2-온
426. 3,3-디메틸-1-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)인돌린-2-온
427. 3,3-디메틸-1-(2-[엑소-6-m-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)인돌린-2-온
428. 1-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-3,3,5-트리메틸인돌린-2-온
429. 3,4-디클로로-N-(2-[엑소-6-p-니트로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤즈아미드
430. 2,5-디플루오로-N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤즈아미드
431. 2-아미노-N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤즈아미드
432. 2-아미노-N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤즈아미드
433. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-2-메틸아미노벤즈아미드
434. N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸)-2-메틸아미노벤즈아미드
435. 3-아미노-N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤즈아미드
436. 4-아미노-N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤즈아미드
437. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)티오펜-2-카르복스아미드
438. 5-클로로-N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)티오펜-2-카르복스아미드
439. 5-클로로-N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)티오펜-2-카르복스아미드
440. 5-클로로-N-(2-[엑소-6-(5-클로로-2-티에닐)-3-아자비시클로-[3.2.0]헵탄-3-일]에틸)티오펜-2-카르복스아미드
441. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤조[b]푸란-2-카르복스아미드
442. 3-클로로-N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤조[b]티오펜-2-카르복스아미드
443. 3-클로로-N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤조[b]티오펜-2-카르복스아미드
444. 3-클로로-N-(2-[엑소-6-p-니트로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤조[b]티오펜-2-카르복스아미드
445. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)인덴-3-카르복스아미드
446. N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)인덴-3-카르복스아미드
447. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)시클로프로판카르복스아미드
448. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.O]헵탄-3-일]에틸)시클로펜탄카르복스아미드
449. N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)시클로펜탄카르복스아미드
450. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)시클로헥산카르복스아미드
451. N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)시클로헥산카르복스아미드
452. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)나프탈렌-1-카르복스아미드
453. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)인돌-2-카르복스아미드
454. N-(2-[엑소-6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)인돌-3-카르복스아미드
455. 엑소-6-p-플루오로페닐-3-[2-(1-나프틸)에틸]-3-아자비시클로[3.2.0]헵탄
456. 엑소-6-p-클로로페닐-3-[2-(1-나프틸)에틸)-3-아자비시클로[3.2.0]헵탄
457. 엑소-6-m-클로로페닐-3-[2-(1-나프틸)에틸]-3-아자비시클로[3.2.0]헵탄
458. 엑소-6-(5-클로로-2-티에닐)-3-[2-(1-나프틸)에틸]-3-아자비시클로
[3.2.0]헵탄
459. 엑소-6-p-플루오로페닐-3-[2-(2-나프틸)에틸]-3-아자비시클로[3.2.0]헵탄
460. 엑소-6-p-플루오로페닐-3-[1-나프틸메틸]-3-아자비시클로[3.2.0]헵탄
461. 엑소-6-p-플루오로페닐-3-[2-나프틸메틸]-3-아자비시클로[3.2.0]헵탄
462. 4-(6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일)-1-(티오펜-2-일)부탄-1-온
463. 4-(6-p-클로로페닐-3-아자비시클로[3.2.0]헵탄-3-일)-1-(티오펜-2-일)부탄-1-온
464. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-4-페닐피롤리딘-2-온
465. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)벤즈옥사졸린-2-온
466. N-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)이소인돌리논
467. 1-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)인다졸
468. 1-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-1,8-나프탈렌술탐
469. 4-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)-1,4-벤즈옥사진-3-온
470. 1-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)퀴녹살린-2(1H)-온
471. 1-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)인돌린-2-온
472. 1-(2-[엑소-6-p-플루오로페닐-3-아자비시클로[3.2.0]헵탄-3-일]에틸)스피로[시클로프로판-1',3-인돌린-2-온]
473. 3,6-디메틸-2-메틸아미노-5-[2-(엑소-6-(2-나프틸)-3-아자비시클로
[3.2.0]헵탄-3-일)에틸]-3H-피리미딘-4-온
474. 3,6-디메틸-2-메틸아미노-5-[2-(엑소-6-(1-나프틸)-3-아자비시클로
[3.2.0]헵탄-3-일)에틸]-3H-피리미딘-4-온
475. 3,6-디메틸-2-메틸아미노-5-[2-(엑소-6-(5-클로로-1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-3H-피리미딘-4-온
476. 3,6-디메틸-2-메틸아미노-5-[2-(엑소-6-(6-클로로-2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-3H-피리미딘-4-온
477. 3,6-디메틸-2-메틸아미노-5-[2-(엑소-6-(9-페난트릴)-3-아자비시클로
[3.2.0]헵탄-3-일)에틸]-3H-피리미딘-4-온
478. 7-메틸-6-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-5H-티아졸로[3,2-a]피리미딘-5-온
479. 3-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1H,3H-퀴나졸린-2,4-디온
480. 3-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1H,3H-퀴나졸린-2,4-디온
481. 6-플루오로-3-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1H,3H-퀴나졸린-2,4-디온
482. 3-[2-(엑소-6-(5-클로로-2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1H,3H-퀴나졸린-2,4-디온
483. 3-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-2-메틸-4H-피리도[1.2-a]피리미딘-4-온
484. 1-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-2(1H)퀴놀론
485. 1-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]인돌린-2-온
486. 1-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-2(3H)벤즈이미다졸론
487. 1-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-3-메틸-2(3H)벤즈이미다졸론
488. N-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]벤즈아미드
489. N-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]벤즈아미드
490. N-[2-(엑소-6-(5-클로로-1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]벤즈아미드
491. 3-[2-(1-나프틸)에틸]-엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄
492. 3-[2-(1-나프틸)에틸]-엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄
493. 1-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1H-벤조[cd]인돌-2-온
494. 1-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1H-벤조[cd]인돌-2-온
495. 3,3-디메틸-1-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1,3-디히드로인돌-2-온
496. 3,3-디메틸-1-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1,3-디히드로인돌-2-온
497. 3,3-디메틸-1-[2-(엑소-6-(6-클로로-2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1,3-디히드로인돌-2-온
498. 5-클로로-N-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-2-티오펜카르복스아미드
499. 5-클로로-N-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-2-티오펜카르복스아미드
500. N-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-4-플루오로벤즈아미드
501. N-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-4-니트로벤즈아미드
502. N-[2-(엑소-6-(6-클로로-2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]벤즈아미드
503. N-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.O]헵탄-3-일)에틸]-4-메톡시벤즈아미드
504. N-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.O]헵탄-3-일)에틸]-4-히드록시벤즈아미드
505. N-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.O]헵탄-3-일)에틸]-3,4-디클로로벤즈아미드
506. N-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]나프탈렌-1-카르복스아미드
507. N-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.O]헵탄-3-일)에틸]나프탈렌-1-카르복스아미드
508. N-[2-(엑소-6-(9-페난트릴)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]벤즈아미드
509. 1-[2-(엑소-6-(6-클로로-2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1H-벤조[cd]인돌-2-온
510. 1-[2-(엑소-6-(9-페난트릴)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]-1H-벤조[cd]인돌-2-온
511. N-[2-(엑소-6-(1-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]이소인돌리논
512. N-[2-(엑소-6-(2-나프틸)-3-아자비시클로[3.2.0]헵탄-3-일)에틸]이소인돌리논
513. (+)-(1S,5R,6S)엑소-1-[2-[6-(4-클로로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸]-3-메틸-2H-1,3-디히드로벤즈이미다졸-2-온
514. (+)-(1S,5R,6S)엑소-1-[2-[6-(4-클로로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸]-3-에틸-2H-1,3-디히드로벤즈이미다졸-2-온
515. (+)-(1S,5R,6S)엑소-1-[2-[6-(4-클로로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸]-3-n-프로필-2H-1,3-디히드로벤즈이미다졸-2-온
516. (+)-(1S,5R,6S)엑소-2-[2-[6-(4-클로로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸]-3,3-디메틸-2,3-디히드로-1,2-벤즈이소티아졸 1,1-디옥시드
517. (+)-(1S,5R,6S)엑소-2-[2-[6-(4-클로로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸]-2,3-디히드로-1,2-벤즈이소티아졸 1,1-디옥시드
518. (+)-(1S,5R,6S)엑소-2-[2-[6-(4-플루오로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸]-3,3-디메틸-2,3-디히드로-1,2-벤즈이소티아졸 1,1-디옥시드
519. (+)-(1S,5R,6S)엑소-2-[2-[6-(4-플루오로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸]-3,3-디에틸-2,3-디히드로-1,2-벤즈이소티아졸 1,1-디옥시드
520. (+)-(1S,5R,6S)엑소-2-[2-[6-(4-플루오로페닐)-3-아자비시클로[3.2.0]헵탄-3-일]에틸]-2,3-디히드로-1,2-벤즈이소티아졸 1,1-디옥시드
Claims (4)
- 중추신경계 질환 치료용 약제의 제조를 위한, 하기 화학식 Ⅰ의 N-치환 3-아자비시클로알칸 유도체 및 이들 유도체와 생리학적으로 허용되는 산과의 염의 용도.<화학식 Ⅰ>상기 식에서,B는 이중 결합을 함유할 수 있는 4-, 5- 또는 6-원 고리이며,R1은 각각 할로겐 원자, C1-4알킬, 트리플루오로메틸, 히드록실, C1-4알콕시, 아미노, 모노메틸아미노, 디메틸아미노, 시아노 또는 니트로기에 의하여 단일치환 또는 이치환되거나, 치환되지 않은 페닐, 나프틸, 페난트릴 또는 티에닐기이고,n은 0, 1, 2, 3 또는 4의 수이며,R2는 1개 또는 2개의 할로겐 원자에 의하여 치환되거나, 치환되지 않은 나프틸기이거나, 또는 하기의 라디칼들 중 하나이다:(상기 식에서,R3은 수소 원자, 히드록실기이거나, 또는 불소, 염소 또는 브롬 원자에 의하여 치환되거나, 치환되지 않은 페닐 라디칼이고,R4는 수소 원자이거나, 또는R3및 R4는 함께 산소 원자이고,R5는 각각 불소, 염소 또는 브롬 원자에 의하여, 또는 히드록실, 니트로, 아미노, C1-4알카노일아미노, C1-4알킬아미노, C1-4알킬 또는 메톡시기에 의하여 단일치환 또는 이치환되거나, 치환되지 않은 페닐, 나프틸 또는 티에닐기이며,R6은 수소 원자 또는 메틸기이고,R7은 각각 불소, 염소 또는 브롬 원자에 의하여, 또는 C1-4알킬, 히드록실, 메톡시, 니트로, 시아노, 트리플루오로메틸, 아미노 또는 디-C1-4알킬아미노기에 의하여 단일치환 또는 이치환되거나, 치환되지 않은 페닐, 나프틸, 벤조푸릴, 벤조티에닐, 티에닐, 인돌릴, N-메틸인돌릴 또는 인데닐기이거나, 또는 C3-7시클로알킬기이고,R8은 수소 원자, 또는 불소 또는 염소 원자, 또는 C1-4알킬, 메톡시 또는 아미노기이며,R9는 수소 원자 또는 메틸기이며,R10은 수소 원자 또는 메틸기이거나, 또는R9와 R10은 고리 탄소 원자와 함께 스피로시클로프로판 고리를 형성하고,R11은 수소 원자, 히드록실, C1-C4알킬 또는 C1-C4알콕시기이거나, 인접한 탄소 원자와 함께 C=O- 또는 C=S기를 형성하고,X 및 Y는 탄소 원자, CH, CH2, NH 또는 C1-C4알킬-N기, 또는 질소 원자이고,Z는 직접 결합, CO기, CS기이거나, 또는 수소 원자가 히드록실, 아미노 또는 C1-C4알콕시기에 의하여 또는 할로겐 원자에 의하여 치환될 수 있는 CH 또는 CH2기이고,A는 수소 원자, 히드록실, 아미노, 메르캅토, C1-C4알킬아미노, 디-C1-C4알킬아미노, C1-C4알킬티오 또는 C1-C4알콕시기이거나, 인접한 탄소 원자와 함께 C=O기를 형성하거나, 또는A는 이중 결합을 비연속적으로 1개 또는 2개 함유할 수 있고 CH 또는 CH2기 중 하나가 질소 또는 황 원자에 의하여 또는 NH 또는 N-CH3기에 의하여 대체될 수 있는, Y에 결합된 C3-C4알킬렌기이고, 이와 같은 A 함유 고리는 불소 또는 염소 원자에 의하여, 또는 메틸, 메톡시, 니트로 또는 아미노기에 의하여 단일 치환되고, 상기 고리가 벤젠 고리인 경우, 이 고리는 불소 또는 염소 원자 또는 메틸, 트리플루오로메틸, 니트로, 히드록실, 메톡시, 아미노, 모노메틸 또는 디메틸아미노기에 의하여 단일치환, 이치환, 또는 삼치환될 수 있으며,X-, Y- 및 Z-함유 고리는 1번 질소 원자에서 C1-C4알킬, 알릴 또는 벤질기를가질 수 있으며, 이중 결합을 비연속적으로 1개 내지 3개 함유할 수 있다).
- 제1항에 있어서, 중독성 질환 치료용 약제의 제조를 위한 용도.
- 제1항 또는 제2항에 있어서, 코카인 중독 치료용 약제의 제조를 위한 용도.
- 제1항 또는 제2항에 있어서, 암페타민 및 암페타민계 물질에 대한 중독 억제용 약제의 제조를 위한 용도.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19854147.3 | 1998-11-24 | ||
| DE19854147A DE19854147A1 (de) | 1998-11-24 | 1998-11-24 | Verwendung von N-substituierten Azabicycloalkan-Derivaten zur Verwendung bei der Bekämpfung der Cocainsucht |
| PCT/EP1999/008734 WO2000030639A1 (de) | 1998-11-24 | 1999-11-12 | Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010080535A true KR20010080535A (ko) | 2001-08-22 |
Family
ID=7888824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020017006445A KR20010080535A (ko) | 1998-11-24 | 1999-11-12 | 중추신경계 질환의 치료를 위한 ｎ-치환 아자비시클로알칸유도체의 용도 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1133293A1 (ko) |
| JP (1) | JP2002530333A (ko) |
| KR (1) | KR20010080535A (ko) |
| CN (1) | CN1328455A (ko) |
| AR (1) | AR021502A1 (ko) |
| AU (1) | AU1775300A (ko) |
| BG (1) | BG105549A (ko) |
| BR (1) | BR9915589A (ko) |
| CA (1) | CA2352526A1 (ko) |
| CZ (1) | CZ20011796A3 (ko) |
| DE (1) | DE19854147A1 (ko) |
| HK (1) | HK1040933A1 (ko) |
| HR (1) | HRP20010472A2 (ko) |
| HU (1) | HUP0104416A3 (ko) |
| IL (1) | IL143181A0 (ko) |
| NO (1) | NO20012538L (ko) |
| PL (1) | PL348758A1 (ko) |
| SK (1) | SK7112001A3 (ko) |
| TR (1) | TR200101476T2 (ko) |
| WO (1) | WO2000030639A1 (ko) |
| ZA (1) | ZA200103976B (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101879919B1 (ko) * | 2013-01-15 | 2018-07-18 | 노파르티스 아게 | 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0519013A2 (pt) | 2004-12-13 | 2009-11-03 | Lilly Co Eli | composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto |
| GB0812310D0 (en) | 2008-07-03 | 2008-08-13 | Syngenta Ltd | Novel herbicides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2717288A (en) * | 1987-11-12 | 1989-06-01 | American Home Products Corporation | Polycyclicamines with psychotropic activity |
| DE4427648A1 (de) * | 1994-08-04 | 1996-02-08 | Basf Ag | N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung |
| DE4341403A1 (de) * | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung |
| DE4427647A1 (de) * | 1994-08-04 | 1996-02-08 | Basf Ag | N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung |
-
1998
- 1998-11-24 DE DE19854147A patent/DE19854147A1/de not_active Withdrawn
-
1999
- 1999-11-12 CA CA002352526A patent/CA2352526A1/en not_active Abandoned
- 1999-11-12 IL IL14318199A patent/IL143181A0/xx unknown
- 1999-11-12 HU HU0104416A patent/HUP0104416A3/hu unknown
- 1999-11-12 AU AU17753/00A patent/AU1775300A/en not_active Abandoned
- 1999-11-12 BR BR9915589-3A patent/BR9915589A/pt not_active IP Right Cessation
- 1999-11-12 EP EP99960974A patent/EP1133293A1/de not_active Withdrawn
- 1999-11-12 WO PCT/EP1999/008734 patent/WO2000030639A1/de not_active Application Discontinuation
- 1999-11-12 KR KR1020017006445A patent/KR20010080535A/ko not_active Application Discontinuation
- 1999-11-12 SK SK711-2001A patent/SK7112001A3/sk unknown
- 1999-11-12 TR TR2001/01476T patent/TR200101476T2/xx unknown
- 1999-11-12 JP JP2000583522A patent/JP2002530333A/ja active Pending
- 1999-11-12 CZ CZ20011796A patent/CZ20011796A3/cs unknown
- 1999-11-12 PL PL99348758A patent/PL348758A1/xx not_active Application Discontinuation
- 1999-11-12 CN CN99813559A patent/CN1328455A/zh active Pending
- 1999-11-24 AR ARP990105979A patent/AR021502A1/es unknown
-
2001
- 2001-05-16 ZA ZA200103976A patent/ZA200103976B/en unknown
- 2001-05-23 NO NO20012538A patent/NO20012538L/no not_active Application Discontinuation
- 2001-05-30 BG BG105549A patent/BG105549A/xx unknown
- 2001-06-21 HR HR20010472A patent/HRP20010472A2/hr not_active Application Discontinuation
-
2002
- 2002-04-12 HK HK02102768.4A patent/HK1040933A1/zh unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101879919B1 (ko) * | 2013-01-15 | 2018-07-18 | 노파르티스 아게 | 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE19854147A1 (de) | 2000-05-25 |
| HUP0104416A3 (en) | 2002-11-28 |
| BG105549A (en) | 2001-12-29 |
| IL143181A0 (en) | 2002-04-21 |
| CA2352526A1 (en) | 2000-06-02 |
| CZ20011796A3 (cs) | 2002-05-15 |
| WO2000030639A1 (de) | 2000-06-02 |
| HRP20010472A2 (en) | 2003-04-30 |
| EP1133293A1 (de) | 2001-09-19 |
| AR021502A1 (es) | 2002-07-24 |
| NO20012538D0 (no) | 2001-05-23 |
| BR9915589A (pt) | 2001-08-07 |
| CN1328455A (zh) | 2001-12-26 |
| ZA200103976B (en) | 2002-05-16 |
| JP2002530333A (ja) | 2002-09-17 |
| NO20012538L (no) | 2001-07-04 |
| TR200101476T2 (tr) | 2001-10-22 |
| PL348758A1 (en) | 2002-06-03 |
| SK7112001A3 (en) | 2001-12-03 |
| HUP0104416A2 (hu) | 2002-04-29 |
| HK1040933A1 (zh) | 2002-06-28 |
| AU1775300A (en) | 2000-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001282734B2 (en) | New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation | |
| KR101542516B1 (ko) | 5,6-다이하이드로-1ｈ-파이리딘-2-온 화합물 | |
| US20140350064A1 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
| JP2024522736A (ja) | がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用 | |
| US20230248738A1 (en) | Medicament for treating cough | |
| SK286864B6 (sk) | Použitie opticky čistého (S,S) reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu fibromyalgie alebo iných somatoformných porúch | |
| US20220048919A1 (en) | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections | |
| ES2327845T3 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su uso como moduladores de 5-ht-6. | |
| CA2332814C (en) | Combination therapy for treatment of refractory depression | |
| JP2001515501A (ja) | 置換された４−アリールメチレン−２−イミノ−２，３−ジヒドロチアゾール及び誘導体及びそれらの製薬的使用 | |
| AU2001282734A1 (en) | New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation | |
| US20250032497A1 (en) | Combination therapies | |
| KR100397525B1 (ko) | 뇌혈관 장해에 수반되는 정신증후치료제 | |
| US10975082B2 (en) | Inhibitor of FLT3 kinase and use thereof | |
| Moghadam et al. | An approach to pharmacological targets of pyrrole family from medicinal chemistry viewpoint | |
| US6818639B2 (en) | Pharmaceutical combination formulation and method of treatment with the combination | |
| KR20010080535A (ko) | 중추신경계 질환의 치료를 위한 ｎ-치환 아자비시클로알칸유도체의 용도 | |
| MXPA01005104A (en) | Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system | |
| WO2018102824A1 (en) | Methods for treating neurodegenerative disease | |
| Slassi et al. | Novel serotonergic and non-serotonergic migraine headache therapies | |
| ZA200503822B (en) | 3-(cyclopenten-1-yl)-benzyl or 3-(cyclopenten-1-yl)-hetero-arylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | |
| TW200524871A (en) | Chemical compounds | |
| WO2013029043A1 (en) | Selective kinase inhibitors | |
| WO2006034788A1 (en) | Combinations of n-(indolecarbonyl-)piperazine derivatives and serotonin reuptake inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20010523 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20030306 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20030731 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20031030 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20030731 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |